510(k) · Cleared
ClearedAvenda Health AI Prostate Cancer Planning Software
Data to Oct 25, 2026 (FDA decisions) Oct 12, 2026 (recalls) Sep 30, 2026 (MAUDE) refreshed weekly
Avenda Health, Inc. · POK Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer
Cleared on Nov 22, 2022 as substantially equivalent to DEN170022 (Quantitative Insights, Inc., 2017) after a 169-day review. Its family tree reaches back 1 generation to 2017.
- Decided
- Nov 22, 2022
- Review
- 169 days
- Class
- Class II
- Product code
- POK
- Recalls
- None
- Predicates
- 1
Its longest line of descent runs back 1 generation to DEN170022 (2017). No later device cites it as a predicate yet.
- Root · 1 generation backDEN170022 QuantXQuantitative Insights, Inc. · 2017
- This deviceK221624 Avenda Health AI Prostate Cancer Planning SoftwareAvenda Health, Inc. · 2022
View FIG. 1 as a table
Line of descent and top descendants
| Generation | Number | Device | Applicant | Decided | Recalls |
|---|---|---|---|---|---|
| −1 | DEN170022 | QuantX | Quantitative Insights, Inc. | 2017 | — |
| 0 (this device) | K221624 | Avenda Health AI Prostate Cancer Planning Software | Avenda Health, Inc. | 2022 | — |
Sources: FDA 510(k) database (decision fields), the FDA summary (predicates and indications), FDA recall and enforcement reports, and MAUDE; processed by 510(k) Report. Verify on FDA.gov · Methodology and accuracy.
Planning a device in POK? A 510(k) Report weighs predicate choices, recall history and review times for a new device like this one.
Top candidate predicates for a new POK device
- #1 K242342 Fetal EchoScanscore 16.7 · 9 generations · no Class I recall
- #2 Held for the reportin the report
- #3 Held for the reportin the report
What was it cleared against? (1)
Devices the submitter claimed this one is substantially equivalent to (*), and reference devices cited for a specific test or feature (†), as written in the FDA summary.
| Type | Number | Device | Decided |
|---|---|---|---|
| * | DEN170022 | QuantXSummary page 5…sisted Diagnostic Software For Lesions Suspicious For Cancer 5.0 510(k) SUMMARY PREDICATE DEVICE [807.92(a)(3)] Quantitative Insights, Inc. QuantX (DEN170022) DEVICE DESCRIPTION [807.92(a)(4)] The Avenda Health AI Prostate Cancer Planning Software (“AI Prostate Cancer Planning Software… | 2017 |
What descends from it?
No later submission names this one as a predicate yet.
Has anything in its family been recalled? (0 Class I)
No FDA recall names this device.
No ancestor or descendant has a Class I recall.
What does this lineage say?
- Its one ancestor has no recall.
- 3 other devices also cite its predicate DEN170022.
How does its category compare?
All POK devicesPOK Computer-Assisted Diagnostic Software For Lesions Suspicious For Cancer: FDA decisions, review times, recalls and adverse event reports over 20 years. 2022, this device’s year, is highlighted.
FDA decisions per year · POK
5in 2025
2026 to Oct 25, outlined.
Median 510(k) review, days · POK
119in 2025
Receipt to decision; years with fewer than 3 clearances left blank.
Recalls per year · POK
No recall names POK since 2007.
Adverse event reports per year · POK
1in 2021
MAUDE reports naming product code POK, not matched to any one device; reports are not rates.
View these four charts as a table
| Year | Decisions | Median 510(k) review, days | Recalls (Class I) | MAUDE reports |
|---|---|---|---|---|
| 2007 | 0 | — | 0 | 0 |
| 2008 | 0 | — | 0 | 0 |
| 2009 | 0 | — | 0 | 0 |
| 2010 | 0 | — | 0 | 0 |
| 2011 | 0 | — | 0 | 0 |
| 2012 | 0 | — | 0 | 0 |
| 2013 | 0 | — | 0 | 0 |
| 2014 | 0 | — | 0 | 0 |
| 2015 | 0 | — | 0 | 0 |
| 2016 | 0 | — | 0 | 0 |
| 2017 | 1 | — | 0 | 0 |
| 2018 | 0 | — | 0 | 0 |
| 2019 | 1 | — | 0 | 0 |
| 2020 | 2 | — | 0 | 0 |
| 2021 | 2 | — | 0 | 1 |
| 2022 | 1 | — | 0 | 0 |
| 2023 | 1 | — | 0 | 0 |
| 2024 | 6 | 161 | 0 | 0 |
| 2025 | 5 | 119 | 0 | 0 |
| 2026 | 5 | 155 | 0 | — |
What is it indicated for?
The Avenda Health AI Prostate Cancer Planning Software is an artificial intelligence (AI)-based decision support software, indicated as an adjunct to the review of magnetic resonance (MR) prostate images and biopsy findings in the prostate oncological workflow. The Avenda Health AI Prostate Cancer Planning Software is designed to support the prostate oncological workflow by helping the user with the segmentation of MR image features, including the…
Read the full statement (365 words)
The Avenda Health AI Prostate Cancer Planning Software is an artificial intelligence (AI)-based decision support software, indicated as an adjunct to the review of magnetic resonance (MR) prostate images and biopsy findings in the prostate oncological workflow. The Avenda Health AI Prostate Cancer Planning Software is designed to support the prostate oncological workflow by helping the user with the segmentation of MR image features, including the prostate; in the evaluation, quantification, and documentation of lesions; and in pre-planning for diagnostic and interventional procedures such as biopsy and/or soft tissue ablation. The device is intended to be used by physicians trained in the oncological workflow in a clinical setting for planning and guidance for clinical, interventional, diagnostic, and/or treatment procedures of the prostate.
The Avenda Health AI Prostate Cancer Planning Software’s lesion characterization functions are intended for use on patients with a pathology-confirmed Gleason Grade Group (GGG) ≥ 2 lesion and for whom corresponding biopsy coordinate information have been uploaded. These functions are indicated for the evaluation of the extent of known disease. Extent of known disease refers to the boundary of a pathology confirmed lesion of GGG ≥ 2 for a particular patient. Specifically, using prostate MR images, biopsy, pathology, and clinical data, the device creates and displays a cancer map that assigns a probability to each voxel within the prostate, indicating its probability for containing clinically significant prostate cancer (csPCa, defined as GGG ≥ 2 ). A user selects a threshold for the cancer map to create a boundary of the lesion. The lesion boundary is assigned an Encapsulation Confidence Score indicating the confidence that all csPCa is encapsulated within the boundary. The Encapsulation Confidence Score is from a lookup table generated by a database of cases with known ground-truth. When interpreted by a trained physician, this information may be useful in supporting lesion characterization and subsequent patient management.
The Avenda Health AI Prostate Planning Software may also be used as a medical image application, for the viewing, manipulation, 3D-visualization, and comparison of MR prostate images. The images can be viewed in a number of output formats including volume rendering. It enables visualization of information that would otherwise have to be visually compared disjointedly.
Indications for use as stated in the FDA summary.
https://510kreport.com/device/K221624 · printed Nov 6, 2026
Cite this page
510(k) Report. “K221624: Avenda Health AI Prostate Cancer Planning Software.” Lineage record from FDA 510(k) data and the FDA summary. Updated Nov 3, 2026. Accessed Nov 6, 2026. https://510kreport.com/device/K221624
Report an extraction error
Are you the manufacturer?
Record history
- FDA decision record loaded May 2, 2026
- Summary read Oct 13, 2026 (extraction version 9eaa42aa01ed)
- Lineage and recalls computed Nov 3, 2026
- Page last updated Nov 3, 2026